Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 8/20 | 0.49 |
| ▸ | CA2 | P00918 | 8/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13968020 | 0.94 | MEN1 (0.49) | TSHRTDP1MEN1GAAKMT2A | |
| SCHEMBL18471596 | 0.94 | TDP1 (0.48) | TSHRTDP1MEN1GAAKMT2A | |
| SCHEMBL31614631 | 0.91 | TDP1 (0.48) | TSHRTDP1MEN1GAAKMT2A | |
| SCHEMBL12341824 | 0.91 | TDP1 (0.50) | TSHRTDP1MEN1GAAKMT2A | |
| SCHEMBL21065333 | 0.90 | TDP1 (0.62) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL4527640 | 0.90 | TDP1 (0.66) | TSHRTDP1MEN1GAAKMT2A | |
| SCHEMBL1509845 | 0.90 | MEN1 (0.50) | TSHRTDP1MEN1GAAKMT2A | |
| SCHEMBL31614625 | 0.90 | TDP1 (0.49) | TSHRTDP1MEN1GAAKMT2A | |
| SCHEMBL7745994 | 0.90 | TDP1 (0.49) | TSHRTDP1MEN1GAAKMT2A | |
| SCHEMBL26040329 | 0.89 | TDP1 (0.51) | TSHRTDP1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133069-B1 | BCR-ABL DIPLOID INHIBITOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | SHENZHEN YONGZE PHARMACEUTICAL CO LTD (CN) | 2019-09-18 | — | — | EP | disclosed |
| US-9969753-B2 | BCR-ABL diploid inhibitor, synthesizing method therefor, and uses thereof | SHENZHEN YONGZE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-15 | — | — | US | disclosed |
| EP-3133069-A1 | BCR-ABL DIPLOID INHIBITOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | Chengdu University (CN) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037061-A1 | BCR-ABL Diploid Inhibitor, Synthesizing Method Therefor, and Uses Thereof | SHENZHEN YONGZE PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037061-A1 | BCR-ABL Diploid Inhibitor, Synthesizing Method Therefor, and Uses Thereof | BCR, ABL1, BOD1L1 | TSHR 3388/4885TDP1 1657/4885MEN1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.